AptarGroup
AptarGroup, also known as Aptar, is a global manufacturer of dispensing packaging, drug-delivery systems, and related healthcare technologies.
Last updated November 4, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
AptarGroup, commonly operating under the Aptar name, is a United States-based manufacturer whose businesses focus on dispensing systems, packaging components, and drug-delivery technologies. Its products are used across consumer and household goods, beauty and personal care, food and beverage, pharmaceuticals, and healthcare. Rather than primarily selling finished consumer products under its own name, Aptar supplies the pumps, valves, closures, containers, delivery mechanisms, and related technologies that enable other companies to package, dispense, administer, or digitally support their products. The company traces its origins to Werner Die & Stamping, which began operations in Cary, Illinois, in 1946. Its early capabilities centered on precision manufacturing and the production of spray valves and pumps for consumer and household applications. The business later developed into a broader packaging and delivery-systems company and was incorporated as AptarGroup in 1992. Its manufacturing footprint expanded internationally, with operations reported in 18 countries, allowing the group to serve multinational customers in both established and emerging markets. Aptar’s consumer-facing technologies include dispensing pumps, spray systems, closures, and airless packaging. These systems are used where controlled delivery, convenience, protection from contamination, or product preservation is important. In beauty and personal care, the company supplies packaging and dispensing solutions for products such as cosmetics and skincare. In food and beverage, its technologies support controlled dispensing and packaging formats. Through acquisitions, Aptar broadened its capabilities in elastomeric components, active packaging materials, airless packaging, and makeup packaging. Healthcare and pharmaceutical delivery became an increasingly important part of the group’s activities. Aptar produces nasal administration systems, pulmonary drug-delivery devices, metered-dose inhaler valves, and single- or two-dose intranasal systems. Its Unidose and Bidose platforms are designed for medicines that require one or two nasal administrations. In 2016, Aptar announced that its liquid-spray delivery system was used for Adapt Pharma’s Narcan naloxone nasal spray. Narcan was authorized as a ready-to-use, needle-free emergency treatment for opioid overdose, and the Aptar system was designed to deliver a single dose without assembly, injection, or specialized medical training. In 2019, the FDA approved Aptar Pharma’s Unidose Powder System for an intranasal rescue treatment for severe hypoglycemia, adding another high-profile application for the company’s needle-free delivery technology. The company has also pursued connected and digitally enabled healthcare. In 2016, Aptar entered an agreement with Becton Dickinson to develop self-injection devices and separately agreed with Propeller Health Partners to develop a digitally connected medication inhaler. Aptar later invested in Propeller Health, which subsequently became part of ResMed. Acquisitions of Cohero Health and Voluntis further extended the company’s exposure to digital respiratory health and digital therapeutics, while its investment in training and patient-onboarding technologies supported the use of drug-delivery devices. Aptar’s expansion has been supported by a series of acquisitions. It acquired Stelmi in 2012 to add elastomeric primary-packaging components, Mega Airless in 2016 for airless packaging, and CSP Technologies in 2018 for active packaging and materials-science capabilities. In 2019, Aptar acquired Nanopharm, Gateway Analytical, and Noble International. FusionPKG, a makeup-packaging company, joined the group in 2020, followed later that year by Cohero Health. In 2021, Aptar acquired Voluntis and an 80% interest in Weihai Hengyu Medical Products, a Chinese manufacturer of elastomeric and plastic components used in injectable drug delivery. The COVID-19 pandemic highlighted demand for pumps, delivery devices, and related packaging. In 2020, Aptar invested in additional molding tools and assembly equipment to accelerate production, although demand continued to challenge available capacity. The group has also publicized sustainability initiatives. It reported that renewable sources supplied 85% of its global electricity consumption at the end of 2020, participated in a reusable-packaging partnership with Loop and TerraCycle, and appeared on sustainability and corporate-responsibility rankings during the late 2010s and early 2020s. Aptar is therefore best understood as a business-to-business technology and manufacturing group whose brand value rests on engineering, regulated healthcare delivery, packaging performance, and global production rather than on direct-to-consumer recognition.
History
AptarGroup’s history began in 1946, when Werner Die & Stamping was established in Cary, Illinois. The original business developed manufacturing expertise in dies, stamping, spray valves, and pumps. These capabilities placed the company in the supply chain for consumer and household products, where reliable dispensing, controlled flow, and efficient packaging were important to product performance. The business was incorporated as AptarGroup in 1992. Under the Aptar identity, it developed from a manufacturer of consumer dispensing components into a diversified supplier of packaging systems and drug-delivery technologies. Its consumer activities came to include pumps, spray mechanisms, closures, airless packaging, and other systems used in beauty, personal care, food, beverage, and household products. Its pharmaceutical activities expanded into nasal delivery, pulmonary delivery, metered-dose inhaler valves, and single- and two-dose intranasal devices. Aptar used acquisitions to broaden both its materials portfolio and its geographic and technical reach. Stelmi, acquired in 2012, added elastomeric primary-packaging components. Mega Airless, acquired in 2016, strengthened airless packaging. CSP Technologies, acquired in 2018, brought active packaging and materials-science capabilities. During 2019, Aptar acquired Nanopharm, Gateway Analytical, and Noble International. These transactions added pharmaceutical testing and development capabilities, analytical expertise, and patient-training or onboarding technologies. FusionPKG joined the group in 2020 and expanded its position in makeup packaging, while Cohero Health added digital respiratory-health capabilities later that year. The company’s pharmaceutical delivery technologies gained public visibility through the opioid-overdose response. In 2016, Aptar announced that its liquid-spray platform provided the delivery system for Adapt Pharma’s Narcan naloxone nasal spray. The system was designed as a ready-to-use, single-shot, unit-dose device that did not require assembly, a needle, or specialized medical training. This application demonstrated how Aptar’s packaging and dispensing expertise could be adapted to urgent medical treatment. Aptar also pursued partnerships in connected and injectable healthcare. In 2016, it entered an agreement with Becton Dickinson to develop self-injection devices and partnered with Propeller Health Partners on a digitally connected inhaler. Aptar invested in Propeller Health in 2018; Propeller later became part of ResMed. In July 2019, the FDA approved Aptar Pharma’s Unidose Powder System for an intranasal rescue treatment for severe hypoglycemia, marking another regulatory milestone for needle-free drug administration. In 2020, the COVID-19 pandemic created exceptional demand for pumps and other delivery systems. Aptar invested in new molding equipment and assembly machines to accelerate output, though the available equipment was still insufficient to fully match demand. The company continued its healthcare and digital expansion in 2021 by acquiring Voluntis, a digital therapeutics company, and an 80% stake in Weihai Hengyu Medical Products, a Chinese producer of elastomeric and plastic components used in injectable drug delivery. Sustainability became another visible part of Aptar’s corporate profile. The company reported that renewable electricity accounted for 85% of its global electricity use at the end of 2020. In 2019, it announced a partnership with Loop, a reusable-shopping platform associated with TerraCycle, to support products delivered in reusable containers. Aptar was listed by Barron’s among the Top 100 Most Sustainable U.S. Companies in 2019, 2020, 2021, and 2022, and by Newsweek among America’s Most Responsible Companies in 2021, 2022, and 2023. It also received an A climate-change rating from the Climate Disclosure Project and appeared on Forbes’ Green Growth 50 list in 2021.
- 2021
Expansion into digital therapeutics and injectable components
[1]Aptar acquired Voluntis and an 80% interest in Weihai Hengyu Medical Products.
- 2020
Production investment during the pandemic
[1]Aptar invested in molding and assembly equipment to respond to increased demand for pumps and delivery systems.
- 2019
Unidose Powder System receives FDA approval
[1]Aptar Pharma’s Unidose Powder System was approved for an intranasal, needle-free rescue treatment for severe hypoglycemia.
- 2018
Acquisition of CSP Technologies
[1]The acquisition added active packaging and materials-science capabilities.
- 2016
Narcan delivery-system collaboration announced
[1]Aptar announced that its liquid-spray platform was used for Adapt Pharma’s Narcan naloxone nasal spray.
- 2012
Acquisition of Stelmi
[1]Aptar acquired Stelmi, adding elastomeric primary-packaging components to its pharmaceutical capabilities.
- 1992
AptarGroup is incorporated
[1]The business was incorporated under the AptarGroup name as it developed into a broader packaging and drug-delivery manufacturer.
- 1946
Werner Die & Stamping begins operations
[1]The company’s predecessor began in Cary, Illinois, developing manufacturing capabilities that later supported spray valves, pumps, and dispensing systems.
Products and positioning
Aptar positions itself as an engineered solutions provider for dispensing packaging, pharmaceutical administration, and healthcare delivery. Its differentiation is based on precision manufacturing, controlled product delivery, device usability, regulatory expertise, and the ability to serve global customers across consumer and healthcare markets.
Packaging
Consumer dispensing systems
Aptar produces pumps, spray valves, closures, and related dispensing mechanisms for consumer and household products. These components are intended to provide controlled, convenient, and repeatable product delivery across applications such as personal care, beauty, food, beverage, and household goods.
Beauty and personal-care packaging
Airless packaging
Airless packaging systems are designed to dispense formulations while limiting exposure to air and helping preserve product integrity. Aptar expanded this capability through its acquisition of Mega Airless and applies it particularly to beauty, cosmetics, skincare, and other sensitive formulations.
Drug delivery
Pharmaceutical nasal delivery systems
Aptar Pharma develops nasal spray and powder systems for pharmaceutical and biotechnology customers. Its platforms include liquid-spray, Unidose, and Bidose devices, supporting single-dose or two-dose intranasal administration without conventional needle-based delivery.
Drug delivery
Pulmonary delivery components
The company manufactures pulmonary drug-delivery technologies, including components for inhalation systems and metered-dose inhaler valves. These products are intended to help pharmaceutical customers administer medicines through inhaled routes with controlled dosing.
Intranasal drug delivery · 2019
Unidose Powder System
The Unidose Powder System is a single-dose, intranasal powder-delivery platform. In 2019, the FDA approved it for use with an intranasal, needle-free rescue treatment for severe hypoglycemia, giving the platform a significant regulatory milestone in emergency medicine.
Pharmaceutical packaging
Elastomeric primary-packaging components
Through Stelmi and Weihai Hengyu Medical Products, Aptar supplies elastomeric and plastic components used in pharmaceutical packaging and injectable drug delivery. These components help form closures and interfaces for medicines that require controlled containment and administration.
Digital healthcare · 2016
Digital medication-delivery technologies
Aptar has developed and acquired technologies that connect medication devices with digital health services. Its activities have included connected inhaler work with Propeller Health, digital respiratory-health capabilities from Cohero Health, and digital therapeutics through Voluntis.
Marketing campaigns
- 2019Loop reusable-packaging partnership
International
Aptar announced a partnership with Loop, a shopping platform associated with TerraCycle, to support the delivery of products in reusable containers and explore packaging models that reduce reliance on single-use formats.
Outcome. The partnership formed part of Aptar’s broader sustainability and circular-packaging positioning.
Brand decisions
2020
Increase manufacturing capacity during the COVID-19 pandemicStrategyBackground
Pandemic-related demand increased pressure on supplies of pumps and other dispensing and delivery systems.
Action taken
Aptar invested in additional molding tools and assembly machines to accelerate production.
Aftermath
The investment expanded capacity, although the company still could not fully match demand.
2016
Support the Narcan nasal-delivery systemProduct launchBackground
The opioid-overdose crisis created demand for an emergency naloxone treatment that could be administered rapidly without an injection or extensive training.
Action taken
Aptar supplied the liquid-spray delivery platform used for Adapt Pharma’s Narcan nasal spray, a ready-to-use, single-dose system.
Aftermath
The product became a prominent example of Aptar’s pharmaceutical delivery technology being applied to emergency treatment.
2016
Expand into self-injection and connected inhaler technologiesStrategyBackground
Aptar sought to extend its packaging and delivery expertise into more integrated healthcare devices and connected medication management.
Action taken
The company entered a self-injection development agreement with Becton Dickinson and a connected-inhaler development agreement with Propeller Health Partners.
Aftermath
Aptar later invested in Propeller Health, which subsequently became part of ResMed.
Recent events
AptarGroup and YAT collaborate on skincare offerings[2]
Reported:
AptarGroup and online skincare solutions company YAT announced a collaboration to develop a range of skincare products and services, combining YAT's product design and development capabilities with Aptar's packaging and dispensing solutions.
AptarGroup acquires 49% stakes in three BTY companies[3]
Reported:
AptarGroup acquired a 49% equity interest in three related companies: Suzhou Hsing Kwang, Suqian Hsing Kwang and Suzhou BTY. The source says financial details were expected to be disclosed by the end of 2019 upon successful completion of the transaction.
Sources3 sources
Cite this profile: Cite the canonical profile. /brand-wiki/aptargroup · Editorial policy · How profiles are compiled